Autonomic Technologies, Inc. (ATI) announces the appointment of Dr.
Shashidhar Kori, M.D. to the position of Chief Medical Officer.
Dr. Kori has more than 30 years experience in the field of
neurosciences. Most recently, Dr. Kori was Vice President of Clinical
Development and Medical Affairs at Allergan and MAP Pharmaceuticals.
Previously he was Senior Director of Clinical Development and Senior
Medical Advisor on the Pain/Migraine Team at GlaxoSmithKline. In these
leadership roles, Dr. Kori led the design and execution of numerous
clinical studies to support product development and commercialization,
built and oversaw an active publication strategy, created a new medical
affairs department, served as liaison to the external scientific and
medical community, and had significant involvement in new product
development and discussions with global regulatory authorities.
In his new role, Dr. Kori is responsible for clinical research, clinical
outcomes, and regulatory submissions. He will oversee development and
execution of all clinical research, including clinical trials of the
ATI™ Neurostimulation System for cluster headache and migraine in the
United States and in Europe. He will also lead interactions with
"Dr. Kori brings a wealth of experience to ATI from many years of work
at leading pharmaceutical companies in the headache space and also as a
physician," said Ben Pless, President and Chief Executive Officer of
AI. "Shashi is widely recognized and well respected in the field of
neurology and neuroscience, and headache in particular. We are pleased
and fortunate to have such a capable and accomplished leader join ATI at
this important point in our company's growth."
In addition to his industry experience, Dr. Kori has a distinguished
academic career. He founded, built, and ran four large pain programs,
including the Pain and Palliative Care Program at Duke University where
he was the Founding Director. He founded and managed large clinical and
residency programs, and he held leadership, teaching, and administrative
posts at Duke University, the University of South Florida College of
Medicine, and Case Western Reserve University. Dr. Kori has held
positions in professional organizations including the American Academy
of Neurology, Southern Pain Society, American Society for Neuroimaging,
and the South Eastern Academic Pain Consortium. He has authored more
than 90 publications, served on editorial boards of medical journals,
and has given more than 150 U.S. and international invited lectures on
pain and headache management.
Dr. Kori received his medical degree from Kasturba Medical College in
Mangalore, India. He completed residencies in Internal Medicine at the
VA Medical Center in Brooklyn, NY, and Neurology at St. Vincent's
Hospital and Medical Center in New York, NY. He served fellowships in
Neuro-oncology, Neuroimmunology and Immunobiology, and Cancer Pain at
Memorial Sloan-Kettering Cancer Center, NY.
About Autonomic Technologies
Autonomic Technologies, Inc. (ATI) is a medical device company focused
on the development and commercialization of innovative therapies for the
treatment of severe headache. The company's initial product, the ATI
Neurostimulation System, is CE marked in Europe for the treatment of
cluster headache and is currently being investigated in a multi-center,
randomized study for the treatment of high frequency, high disability
The ATI Neurostimulation System was voted #2 among the Cleveland
Clinic's top 10 medical innovations for 2013 and was chosen to receive a
2013 Best of What's New Award from Popular Science in the Health
category. ATI was named one of FierceMedicalDevices' 2012 Fierce 15 most
promising privately held medical device and diagnostics companies in the
ATI is headquartered in the San Francisco Bay Area and is backed by blue
chip investors Kleiner Perkins Caufield and Byers, InterWest Partners,
Versant Ventures, Novartis Ventures, Aberdare Ventures, and the
Cleveland Clinic. For more information, visit www.ati-spg.com.
[ Back To NFVZone's Homepage ]